key: cord-0763318-cy3wp7mr
authors: Brenner, Erica J.; Ungaro, Ryan C.; Colombel, Jean-Frederic; Kappelman, Michael D.
title: Response to: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients with Inflammatory Bowel Diseases: Results from an International Registry
date: 2021-01-13
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.01.020
sha: 722415149bee808ad0e2489beb18802ca2f099bf
doc_id: 763318
cord_uid: cy3wp7mr

nan

We thank Drs. Brain, Capello, and Magro and their collaborators for their thoughtful replies to our manuscript.

Dr. Capello et al. highlights the preliminary evidence that biologics may attenuate the cytokine storm phase of COVID-19 as a possible explanation for a protective role of TNF antagonists in COVID-19. Our team agrees that the favorable results seen in multiple case series where TNF antagonists were used to treat COVID-19 lend exciting credibility to this assertion 1, 2 , although we await the results of ongoing clinical trials (including NCT04425538) before drawing more definitive conclusions.

Dr. Capello et al. also suggest that the proportion of reported patients treated with TNF antagonist therapy is higher than would be expected. Through January 5 th , 2021, this proportion has remained relatively stable at 42% (1812/4280). 3 We agree that IBD providers may see patients on TNF antagonists more frequently and/or perform COVID-19 testing more readily, and thus have greater awareness of mild COVID-19 in this patient population. Providers may also be more likely to report such cases to SECURE-IBD. We readily acknowledge that comparisons between anti-TNF and other medications may be subject to detection and/or reporting bias. However, the largely favorable outcomes among patients on TNF antagonists can reassure patients and providers that it is safe to continue these medications during the pandemic.

Conversely, Dr. Brain et al. notes that the proportion of patients on TNF combination therapy is lower than that seen in some studies. As of January 5 th , 2021, the proportion of anti-TNF treated patients on combination therapy remains relatively stable at 22%. 3 Gut that substantiates the findings in this manuscript and reports a higher risk of severe COVID-19 outcomes associated with TNF antagonist combination therapy with thiopurines. 4 We have additionally published reports exploring outcomes among IBD patients on tofacitinib 5 , and we will have more data on non-TNF biologics shortly. We also encourage other groups to pursue similar studies in different populations and data sources, as consistency of findings observed by different persons in different places with different samples is one of the key criteria for causation established by Sir Austin Bradford Hill. 6 Regarding the surprising findings related to mesalamines (5-ASA), we agree with the letter authors that there is the potential for reporting bias as milder cases of COVID-19 in patients on 5-ASA may have been less likely to come to the attention of gastroenterologists compared to patients on biologics or immunomodulators, particularly early in the pandemic when testing may have not been as easily available. In our recent paper in Gut, we further explored the 5-ASA association. 2 5-ASA monotherapy was significantly associated with severe COVID-19 when compared to TNF antagonists. This effect was seen in both UC and CD and was most significant in older patients (age 50 or older), in whom most events occurred. In contrast, we did not observe a dose-response association between 5-ASA and severe COVID-19 and there was no signal when comparing 5-ASA monotherapy to patients on no medications, although patients on no medications represent a heterogeneous population and are not the best comparison population. We greatly appreciate the potential mechanistic explanations for this association presented by Magro et al. However, we agree that the current data do not warrant any major J o u r n a l P r e -p r o o f changes in 5-ASA prescription patterns but call for further studies. In the interim, we propose limiting 5-ASA to indicated and high-value clinical situations.

We hope the IBD community will stay tuned as we explore risk associations with other IBD medications and will visit our website www.covidibd.org for current data and updates. This registry would not be possible without the help of the international IBD community, to which we are incredibly grateful.

Sincerely, Erica J Brenner, Ryan C Ungaro, Jean-Frederic Colombel, and Michael D Kappelman

SECURE-IBD